Stock Research: Castle Biosciences

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Castle Biosciences

NMQ:CSTL US14843C1053
73
  • Value
    45
  • Growth
    5
  • Safety
    Safety
    90
  • Combined
    45
  • Sentiment
    92
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The company operates in the healthcare industry, focusing on diagnostic tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with products including DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. No specific regions of operation are mentioned. In the last fiscal year, the company had a market cap of $549 million, profits of $272 million, revenue of $332 million, and 761 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 7 35 26
Growth
5 24 11 55
Safety
Safety
90 79 73 84
Sentiment
92 65 69 47
360° View
360° View
73 25 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
95 97 93 97
Opinions Change
83 70 50 26
Pro Holdings
n/a 19 39 3
Market Pulse
75 40 47 72
Sentiment
92 65 69 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 7 35 26
Growth
5 24 11 55
Safety Safety
90 79 73 84
Combined
45 13 16 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
43 7 12 3
Price vs. Earnings (P/E)
28 4 78 24
Price vs. Book (P/B)
52 59 80 59
Dividend Yield
1 1 1 1
Value
45 7 35 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
14 4 27 74
Profit Growth
8 92 32 6
Capital Growth
15 6 18 95
Stock Returns
69 53 19 21
Growth
5 24 11 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
59 91 94 90
Refinancing
68 96 92 94
Liquidity
93 4 1 15
Safety Safety
90 79 73 84

Similar Stocks

Discover high‑ranked alternatives to Castle Biosciences and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: